NCT05784883

Tricuspid Regurgitation in the ElderlY

Prevalence, Mechanisms, and Outcome of Tricuspid Valve Regurgitation in the Elderly
Al-Azhar University·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Tricuspid Regurgitation
Drug/Device/Intervention
Echocardiography
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Al-Azhar University
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2022
End date
Aug 01, 2029
Enrollment
700 participants
Primary outcome

Prevalence of tricuspid valve regurgitation in the elderly,All-cause mortality,Cardiovascular mortality,Rehospitalization for congestive heart failure

Summary

Tricuspid regurgitation (TR) is the second most common VHD after MR. Its prevalence also
 increases with age, with an estimated incidence of up to 6% in elderly population. When
 adjusted to age (among other confounders), survival is worse for patients with moderate and
 severe TR. We aim to explore the prevalence, mechanisms, and clinical implications of
 tricuspid valve regurgitation in elderly subjects screened at a tertiary center in Cairo,
 Egypt.

ICD-10 classifications
Tricuspid stenosisTricuspid stenosis with insufficiencyNonrheumatic tricuspid (valve) stenosisTricuspid insufficiencyNonrheumatic tricuspid (valve) stenosis with insufficiency
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05784883
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05784883 through Pure Global AI's free database. This phase not specified trial is sponsored by Al-Azhar University and is currently Recruiting. The study focuses on Tricuspid Regurgitation. Target enrollment is 700 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.